Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
This study is an observational safety surveillance study designed to prospectively assess patients with high-grade osteosarcoma who are candidates for treatment with mifamurtide within the context of prevailing standard oncology practice
Osteosarcoma
DRUG: Mifamurtide
Short-term safety profile of mifamurtide during treatment (mifamurtide in combination with chemotherapy), * Adverse events of special interest (AESIs), including important identified and potential risks
* The frequency and pattern of mifamurtide-related infusion adverse events, 36 weeks|The long-term safety profile of mifamurtide during and following treatment (mifamurtide in combination with chemotherapy), Assessment of AESIs, consisting of important identified and potential risks, Up to 5 years from the last dose of mifamurtide or until death
Disease-free survival, Up to 5 years from the last dose of mifamurtide or until death|Overall Survival, Up to 5 years from the last dose of mifamurtide or until death
This study is an observational safety surveillance study designed to prospectively assess patients with high-grade osteosarcoma who are candidates for treatment with mifamurtide within the context of prevailing standard oncology practice